Equities research analysts at Zacks Research upped their Q1 2026 earnings per share estimates for Pfizer in a report released ...

Some stocks pay juicy dividends for a while only for the income to later dwindle. Others generate consistent and reliable dividends over the long run. Want decades of passive income? Here are three ...

Pfizer (PFE) has agreed to pay nearly $60M to resolve allegations that its Biohaven unit paid kickbacks to induce ...

Ascentage Pharma Group (AAPG) (AAPGV) (ASPHF), which is backed by Takeda (TAK), has priced a $126M U.S. initial public offering. Read more here.

Pfizer Inc. (NYSE:PFE – Get Free Report) saw unusually large options trading activity on Thursday. Traders acquired 251,131 ...

Pfizer Inc. closed 16.17% below its 52-week high of $31.54, which the company achieved on July 30th.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

For many investors, the main point of stock picking is to generate higher returns than the overall market. But if ...

Abbott also is a buy for its dividend strength. As a Dividend King it's raised its dividend for more than 50 consecutive ...

In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...